- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
drug development biotechnology NIH economic development vaccines economy patent Animal biotechnology 2012 BIO International Convention BIO Technology Transfer BIO International Convention biotech industry FDA USPTO United States Patent and Trademark Office BIOTECH Intellectual Property Patent Reform innovationAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Category Archives: Public Policy
Latest From Public Policy
Bayh Dole Act a failure?
By Guest Writer Joseph Allen One hotly debated topic in Washington of real importance to the biotechnology community is how well the annual multi-billion dollar federal investment in R&D is being translated into new products, jobs and companies needed to improve the lives of US taxpayers and help pull the US economy out of its current doldrums. An interesting insight on the debate is captured in a Washington Post article “Innovation’s golden opportunity” that ran Read More >
Taiwan’s Translational Research (or lack thereof)
Brady Huggett concludes in this article that, “… perhaps the biggest strike against Taiwan is a lack of translational research. There is no collective mindset that envisions products from research. And if biotech is to drive the future economies of countries around the globe, there has to be nationwide efforts to turn academic research and publicly-funded lab work into something that can benefit patients and be sold. We’ve talked about it before on this blog Read More >
Myriad Genetics’ actions justify a ban on gene patents?
The following information was provided by Myriad’s General Counsel during his presentation on the subject during a recent BIO IP conference: In order to develop and then ensure the widest possible distribution of the Myriad BRCA diagnostic test, Myriad needed to make the initial discovery, educate the medical community on the values of personalized medicine (the BRCA test), convince insurance companies to cover the test, and educate the patient community. All of these activities took Read More >
Banning Gene Patents Will Promote Innovation?
Abolishing gene patents will deter, not promote, innovation, as the patent eligibility of isolated DNA molecules provides incentives necessary for development of life-enhancing diagnostics and therapeutics. R&D to identify genes, their sequences, genetic variations, and their disease correlation is very costly. Claims like those of the patents at issue in the Myriad Genetics lawsuit have been a key foundation supporting the massive investment of time and capital that is necessary to bring life-enhancing DNA-based diagnostics Read More >
Celebrating 30 Years of Biotechnology Innovation: From Diamond v. Chakrabarty to Today
David Kappos, Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO), provided opening remarks at an event entitled, Celebrating 30 years of Biotechnology Innovation: From Diamond v. Chakrabarty to Today during the 2011 BIO International Convention. The forum, co-sponsored by the US Patent and Trademark Office, The Biotechnology Industry Organization and the Biojudiciary Project, celebrated the 30th anniversary of the issuance of the patent from the Supreme Read More >
